October 24, 2020

The Niche

Knoepfler lab stem cell blog

fat stem cells

6 min read

Is it the beginning of the end for dubious American clinics that sell transplants of unproven and non-FDA approved fat stem cell injections? As the year of 2014 was winding down, the FDA issued two key new draft guidances (see here and here) that could prove to be crash diets for these burgeoning fat stem cell clinics. (Update: As of 2020, the FDA has now clearly defined fat stem cells as drug products and filed suit against two firms marketing unapproved fat stem cells.) These new FDA guidances indicate …Read More

5 min read

I recently interviewed Drs. Elliot Lander and Mark Berman of the Cell Surgical Network, an affiliated chain of clinics selling stem cell interventions for more than a dozen medical conditions. You can read Part 1 here and Part 2 here of the interview where we cover 10 important questions. Today is Part 3, where I explain why their answers deeply trouble me. First, let me answer a question myself: why interview the leaders of the Cell Surgical Network, especially if I felt going into it that I would …Read More

6 min read

Today I am posting Part 2 of my interview with Drs. Lander and Berman of the Cell Surgical Network. You can read Part 1 here, which is an interesting look inside the Network. The final portion of this blog post series, Part 3, is my take on their answers and you might not be surprised that I often disagree with them. Today, the questions are focused on some very critical issues for the Cell Surgical Network including potential FDA regulatory factors for the Network, the …Read More

5 min read

The Cell Surgical Network is a large and growing group of affiliated stem cell clinics across the US. The Network providers use stromal vascular fraction (SVF) interventions for a host of conditions on a for-profit basis. Drs. Elliot Lander and Mark Berman lead the Network. They agreed to do a Q&A interview with me. Below is Part 1, which delves into the Network itself. Part 2 on SVF, the FDA, and issues of homologous use can be read here. Part 3 of this series is my reaction …Read More